Appeals system and its outcomes in national health insurance in Taiwan

The Annals of Pharmacotherapy
Swu-Jane LinYea-Huei Kao Yang

Abstract

Prior authorization has been used extensively as one of the mechanisms to control costs and ensure quality of care by the National Health Insurance (NHI) plan in Taiwan. An appeals system, the Dispute Mediation Committee (DMC), independent of the NHI, is available for interested parties to dispute denials of prior authorization. Currently, medications for Alzheimer's disease constitute the largest category of appeals. To describe the appeals system and analyze outcomes of cases of medications for Alzheimer's disease submitted to the Bureau of NHI (BNHI) for prior authorization and to the DMC for appeals. Prescriptions of donepezil and rivastigmine submitted for prior authorization from 2000 through 2002 were analyzed. Cases denied prior authorization and later submitted as appeals to the DMC were summarized with descriptive and bivariate methods. A total of 12,237 cases of donepezil and 6975 cases of rivastigmine were submitted to the BNHI for prior authorization; among them, 72.6% of donepezil and 66.5% of rivastigmine cases received authorization. Among the thousands of cases denied prior authorization, 124 appealed to the DMC for dispute resolution. The result of the majority of the appeals (111 [89.5%]) was to uphold the BN...Continue Reading

References

Aug 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C WhiteS B Greenberg
Aug 3, 1999·American Journal of Preventive Medicine·J R MorrowS N Blair
Nov 5, 1999·Archives of Internal Medicine·V G FreemanD P Sulmasy
Apr 19, 2000·JAMA : the Journal of the American Medical Association·M K WyniaI B Wilson
Feb 15, 2001·Archives of Internal Medicine·I B WilsonB Hillman
Jan 5, 2002·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·D T BessA Alderson
May 22, 2002·Archives of Internal Medicine·Rachel M WernerPeter A Ubel
Oct 26, 2002·The Annals of Pharmacotherapy·Aiman A MomaniDavid P Nau
Apr 3, 2003·Clinical Neuropharmacology·David Knopman
Sep 12, 2003·The New England Journal of Medicine·Claudia H Kawas
Nov 25, 2003·Annals of Emergency Medicine·David J KarrasUNKNOWN EMERGEncy ID NET Study Group
Mar 5, 2005·BMJ : British Medical Journal·Zosia Kmietowicz
May 5, 2005·Journal of Health and Social Behavior·Peter Conrad
Aug 6, 2005·BMJ : British Medical Journal·Hanna KaduszkiewiczHendrik van den Bussche

❮ Previous
Next ❯

Citations

Jan 19, 2007·International Journal of Mental Health Nursing·Wei-Chen Tung, Susan L Beck
Aug 16, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Tzu-Chi HsuLi-Tzong Chen
Aug 29, 2013·The British Journal of Dermatology·T-C HuaH-N Liu
Jun 21, 2017·Journal of Attention Disorders·Nian-Sheng TzengWu-Chien Chien
May 24, 2007·International Journal of Geriatric Psychiatry·Jong-Ling Fuh, Shuu-Jiun Wang
Feb 7, 2018·The American Journal of the Medical Sciences·Nian-Sheng TzengWu-Chien Chien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.